Smith & Nephew Shares Fall On Lower Margins As Cost Headwinds Hit Q2 Profit

  • Smith & Nephew Plc SNN reported Q2 revenue of $1.29 billion, up 1.2% on an underlying basis but down 3.1% on a reported basis, including a 430 basis point foreign exchange headwind.
  • Orthopedics revenue declined 1.1%, or by 4.9% on a reported basis, reflecting execution and supply chain challenges.
  • Sports Medicine and ENT were up 1.9%, but down 2.4% on a reported basis, with growth “significantly impacted” by the Covid-related lockdown in China.
  • Advanced wound management grew 3.8% but fell 1.3% on a reported basis, with all regions and segments contributing.
  • Its operating profit margin was 9.3%, compared to 9.2% a year ago, while EPS slipped to 20.2 cents from 23.4 cents.
  • The company’s 1H trading profit totaled $440 million, down from $459 million, as the margin declined from 17.6% to 16.9%, reflecting higher input inflation.
  • Guidance: Smith & Nephew unchanged full-year underlying revenue growth guidance of 4.0% - 5.0%.
  • Meanwhile, its trading profit margin was expected to be around 17.5%, reflecting a prolonged inflationary impact and continued external supply challenges.
  • “After only a few months at Smith & Nephew it is clear to me that we have many more opportunities than challenges,” said CEO Deepak Nath.
  • Nath said orthopedics continued to be held back by execution and supply chain challenges.
  • Price Action: SNN shares are down 10.30% at $26.32 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!